Investors Purchase Large Volume of Quantum-Si Call Options (NASDAQ:QSI)

Quantum-Si incorporated (NASDAQ:QSI) was the target of some unusual options trading activity on Wednesday. Investors bought 3,994 call options on the company. This is an increase of 3,343% compared to the typical volume of 116 call options.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of QSI. XTX Topco Ltd purchased a new stake in shares of Quantum-Si during the 2nd quarter worth $25,000. Public Employees Retirement System of Ohio acquired a new position in Quantum-Si during the first quarter worth about $27,000. SG Americas Securities LLC purchased a new position in Quantum-Si in the third quarter valued at about $53,000. Virtu Financial LLC acquired a new stake in shares of Quantum-Si during the 1st quarter valued at approximately $98,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Quantum-Si by 11.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 59,727 shares of the company’s stock worth $118,000 after acquiring an additional 5,945 shares in the last quarter. Institutional investors and hedge funds own 39.90% of the company’s stock.

Quantum-Si Trading Down 12.2 %

Shares of QSI opened at $1.22 on Friday. The stock’s 50 day moving average is $0.86 and its two-hundred day moving average is $1.09. Quantum-Si has a twelve month low of $0.61 and a twelve month high of $2.43. The firm has a market capitalization of $173.79 million, a PE ratio of -1.91 and a beta of 2.89.

Analyst Ratings Changes

QSI has been the topic of a number of recent research reports. Canaccord Genuity Group dropped their target price on Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, November 13th. HC Wainwright lifted their price objective on shares of Quantum-Si from $4.00 to $5.50 and gave the company a “buy” rating in a research report on Thursday.

About Quantum-Si

Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments.